A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
Clinical trial NCT03138499 · TERMINATED
Trial details
- NCT number
- NCT03138499
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-26
- Primary completion
- 2021-02-22
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.